Antibody Drug Conjugate Market Key Regions, Industry Players, Opportunity and Application by 2030

 Market Analysis

The global antibody drug conjugate (ADC) market is projected to witness a stupendous growth at a notable 16.70% CAGR over the predicted years. ADCs are made of three parts- first a specific antibody for binding, an antigen that has limited expression on the normal cells, second a cytotoxic agent to kill target cancer cells and third a chemical linker to attach the cytotoxic agent to the antibody. This is how antibody drug conjugates work. They are the new age of therapeutic agents. One of the key advantages of antibody drug conjugates is that this will help in bringing together the finest characteristics of both antibodies as well as the chemotherapy’s cytotoxic potential.

There are many factors that is fueling the growth of the antibody drug conjugate market. The different market trends and factors in this market according to an analysis performed by Market Research Future (MRFR) include increasing prevalence of cancer, advancement in medical technology, increased investment in R & D, efficacy of ADC in treating diseases, rising collaboration amid biotechnology and biopharmaceuticals and research institutes, preclinical research, growing geriatric population and rise in obese population. On the contrary, the soaring cost related to the procedure may hamper the growth of the antibody drug conjugate market.

Market Segmentation

As per MRFR report, the global antibody drug conjugate market is segmented on the basis of type, product, technology, application and end-user.

Based on type, it is segmented into drug/toxin, linker, monoclonal antibodies and others. Of these, the antibody drug conjugate linker is expected to have the maximum share in the antibody drug conjugate market.

Based on application, the antibody drug conjugate market is segmented into lymphoma, multiple myeloma, solid tumors, skin cancer, breast cancer, colon cancer, lung cancer, glioblastoma, ovary cancer, pancreas cancer, kidney cancer, prostate cancer and leukemia. Leukemia is further segmented into Chronic Lymphocytic Leukemia (CLL), Acute Lymphocytic Leukemia (ALL), Chronic Myeloid Leukemia (CML), and Acute Myeloid Leukemia (AML). Of these, breast cancer had the maximum share owing to its increasing prevalence.

Based on product, it is segmented into Kadcyla, Adcertis and others.

Based on technology, the antibody drug conjugate market is segmented into Immunomedics technology, Seattle Genetics technology, ImmunoGen technology and others.

Based on end-user, it is segmented into biopharmaceutical companies, biotechnology companies, academic research institutes, specialized cancer and others.

Browse Complete Report @ https://www.marketresearchfuture.com/reports/antibody-drug-conjugate-market-1113
Regional Analysis

Based on region, the antibody drug conjugate market covers growth opportunities and latest trends across North America, Europe, Asia Pacific and Middle East and Africa. Of these, North America is expected to accrue maximum share in the market due to advancement in manufacturing techniques, technological innovation and contribution of nanotechnology to create ADC. The U.S. FDA has given approval to only three ADC. The antibody drug conjugate market in Europe will have the second largest share followed by the APAC region. APAC is an emerging market and the factors that are driving the growth of the market include increasing government initiatives. A good number of products are under the pipeline and such developments are performed under license agreements.

Key Players

Leading players profiled in the antibody drug conjugate market include Synthon (U.S.), Mersana Therapeutics (U.S.), Oxford BioTherapeutics (U.S.), Heidelberg Pharma (Germany), Progenics Pharmaceuticals (U.S.), Astellas Pharma/Agensys (Japan), Bayer HealthCare (Germany), Agensys, Inc. (U.S.), Concortis Biotherapeutics (U.S.), Genentech (U.S.), AbbVie Inc. (U.S.), Millennium Pharmaceuticals (U.S.), Celldex Therapeutics (U.S.), Pfizer Inc. (U.S.), Immunomedics (U.S.), Antikor (U.K.), Roche Holding AG (Switzerland), ImmunoGen, Inc. (U.S.), and Seattle Genetics (U.S.).

Feb 2019- The Food and Drug Administration (FDA) has granted priority review to ADC (antibody drug conjugate) for diffusing large B-Cell Lymphoma. The chief medical officer of global product development is working with the Food and Drug Administration for bringing this vital novel option to patients having this aggressive ailment as fast as possible. The FDA is most likely to come up with the decision by August 19, 2019.

Jan 2019- Daiichi Sankyo has come up with a late-stage study of ADC to treat patients having low expressing HER2 metastatic/unresectable breast cancer.

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street, 5Th Floor,

New York, New York 10013

United States of America

+1 628 258 0071

Email: sales@marketresearchfuture.com

Comments

Post a Comment

Popular posts from this blog

Acute Care EHR Market Focuses on SWOT analysis, Synopsis, Development Plans 2020 to 2027

  Overview The acute care EHR slightly differ from the hospital and ambulatory EHR, generating patient information with all clinical details including the operating room, emergency department, ICU, and inpatient unit. Over the past decade, there has been a significant rise in the number of patients suffering from chronic diseases such as cancer, diabetes, heart disease, and stroke among others which are driving the acute care EHR market, increasing the number of caregiving facilities across the globe. Recognizing the exponential growth, the market perceives currently and gauging the potential the market holds to grow in the years to come; Market Research Future (MRFR), in its recently published market forecast asserts that the global  acute care EHR market  will grow exponentially by 2023, registering approximately 7% CAGR during the forecast period (2020 – 2027). The global acute care EHR is majorly driven by the augmenting demand for the remote health monitoring for geriatric patient
Read more

mHealth Market Latest Study Focuses On Current, Future Innovations and Top Key Vendors | Forecast 2030

  Market Overview The wave of modernization in the healthcare sector has led to the penetration of the concept of mHealth greatly. Reports that gauge the healthcare IT industry has been made available by Market Research Future which creates reports on several industry verticals that review the market growth and prospects. The market is forecasted to achieve a 36.5% CAGR in the upcoming forecast period. The robust growth pace in the wearable health device sector has increased the expansion of the  mHealth market  globally. Moreover, increased usage of smartphones is also playing a key role in the growth of the market. Also, patients are increasingly involved and aware of their treatments which is expected to further influence the mHealth market in the forecast period. Segmental Analysis The segmental evaluation of the mHealth market is carried out on the basis of therapeutics, applications, and region. On the basis of therapeutics, the mHealth market has been segmented into respiratory,
Read more

Cardiac Monitoring and Cardiac Rhythm Management Device Market Growth, Opportunity and Product Developments 2030 |MRFR

  Market Highlights The increasing demand for minimally invasive surgeries drives the growth of this market. Advanced technologies in cardiac monitoring and cardiac rhythm management devices have also led to growth in this market.  However, factors such as stringent regulatory approval procedures, the high cost of cardiac devices, and lack of reimbursement policies in developing countries are hindering the growth of the market. Rising prevalence of cardiovascular diseases and the increasing number of unmet medical needs in undeveloped countries are leading to the growth of the  cardiac monitoring and cardiac rhythm management device ma rket . Technical advancements in drug-eluting, MRI compatible pacemakers, and Holter monitors are some of the factors leading to the growth of this market. The growth of the global cardiac monitoring device market is driven by the high prevalence of cardiovascular disorders worldwide. Regional Analysis The market in the Americas is expected to dominate t
Read more